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Background: Mild therapeutic hypothermia (HT) has been implemented in the management of post cardiac arrest
(CA) syndrome after the publication of clinical trials comparing HT with common practice (ie, usually hyperthermia).
Current evidence on the comparison between therapeutic HT and controlled normothermia (NT) in CA survivors,
however, remains insufficient.
Methods: Eight female swine (sus scrofa domestica; body weight 45 kg) were randomly assigned to receive either mild
therapeutic HT or controlled NT, with four animals per group. Veno-arterial extracorporeal membrane oxygenation
(ECMO) was established and at minimal ECMO flow (0.5 L/min) ventricular fibrillation was induced by rapid ventricular
pacing. After 20 min of CA, circulation was restored by increasing the ECMO flow to 4.5 L/min; 90 min of reperfusion
followed. Target core temperatures (HT: 33°C; NT: 36.8°C) were maintained using the heat exchanger on the
oxygenator. Invasive blood pressure was measured in the aortic arch, and cerebral oxygenation was assessed using
near-infrared spectroscopy. After 60 min of reperfusion, up to three defibrillation attempts were performed. After 90
min of reperfusion, blood samples were drawn for the measurement of troponin I (TnI), myoglobin (MGB), creatine-
phosphokinase (CPK), alanin-aminotransferase (ALT), neuron-specific enolase (NSE) and cystatin C (CysC) levels. Reactive
oxygen metabolite (ROM) levels and biological antioxidant potential (BAP) were also measured.
Results: Significantly higher blood pressure and cerebral oxygenation values were observed in the HT group (P<0.05).
Sinus rhythm was restored in all of the HT animals and in one from the NT group. The levels of TnI, MGB, CPK, ALT, and
ROM were significantly lower in the HT group (P<0.05); levels of NSE, CysC, and BAP were comparable in both groups.
Conclusions: Our results from animal model of cardiac arrest indicate that HT may be superior to NT for the
maintenance of blood pressure, cerebral oxygenation, organ protection and oxidative stress suppression following CA.
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Mild therapeutic hypothermia (HT) was introduced into
the clinical management of cardiac arrest survivors after
the publication of the results of two clinical trials showing
a benefit compared with standard treatment [1,2], and
has been included in the guidelines for post-cardiac arrest
care from the American Heart Association [3] and the
European Resuscitation Council [4]. The implementation
of HT into clinical practice was also supported by meta-
analyses of these clinical trials [5,6]. Recently, however,
several authors presented a critical view of the current evi-
dence for the protective role of HT in post-cardiac arrest
syndrome. In analyses of the available randomized data,
they showed that the evidence for the benefits of HT in
cardiac arrest survivors remains inconclusive [7,8]. Their
criticisms were based on the small size of published trials,
low-quality data and non-negligible risks of systematic
and random errors [7,8]. Furthermore, in the published
studies, HT was compared with standard care without
specific temperature management, ie, usually with spon-
taneously developed fever. The deleterious effects of fever
and hyperthermia have been repeatedly observed in a wide
population of critically ill patients [9] as well as in cardiac
arrest survivors [10,11]. The relative lack of evidence
regarding the benefits of mild therapeutic HT in cardiac
arrest survivors has led to the establishment of a large
multicenter randomized controlled trial comparing mild
therapeutic HT with controlled normothermia (NT) in
CA survivors (the Target Temperature Management trial),
which is currently underway [12].
Presently, there is minimal research comparing mild
therapeutic HT with controlled NT in either human
studies [13] or animal experiments [14]. Therefore, the
aim of the present study was to compare the effects of
mild therapeutic HT and controlled NT on several clin-
ically relevant outcomes in an animal model of cardiac
arrest. We tested the hypothesis that mild HT is super-
ior to controlled NT in the maintenance of blood pres-
sure and cerebral oxygenation, resuscitability, prevention
of organ damage and oxidative stress suppression after
cardiac arrest in a porcine model.
Methods
The present study was approved by the Charles University
1st Medical School Institutional Animal Care and Use
Committee and performed at the Animal Laboratory,
Department of Physiology, 1st Medical School, Charles
University in Prague, Czech Republic, in accordance with
Act No 246/1992 Coll. regarding the protection of animals
against cruelty.
Animal model
Eight female swine (Sus scrofa domestica, Landrace ×
Large white crossbreed), four to five months of age, witha mean body weight of 45 kg were included in the ex-
periment. After 24 hr of fasting, general anesthesia was
induced by administration of azaperone (2 mg/kg IM)
followed by atropine sulphate (0.02 mg/kg IM) and keta-
mine hydrochloride (15 to 20 mg/kg IM). Anesthesia was
continued with initial propofol and morphine boluses
(2 mg/kg IV and 0.1 to 0.2 mg/kg IV, respectively) and
animals were orotracheally intubated. Continuous IV in-
fusions of propofol (8 to 10 mg/kg/hr) and morphine (0.1
to 0.2 mg/kg/hr) were used to maintain anesthesia. The
doses were adjusted according to physiological parame-
ters, photoreaction, corneal and palpebral reflexes, lacri-
mation and spontaneous movement. At the end of the
experiment, potassium chloride (2 meq/kg) in conjunction
with general anesthesia was used to euthanize animals.
Bilateral femoral (arterial and venous) and jugular ap-
proaches were used for multiple sheath insertions by the
standard percutaneous Seldinger technique. An initial
rapid IV infusion of 1000 ml of normal saline was given
after anesthesia induction, followed by a continuous IV
drip of 200 to 500 ml/hour to reach and maintain a mean
right atrial pressure of 3 to 7 mmHg. An unfractionated
heparin bolus (100 U/kg IV) was given after sheath place-
ment, followed by a continuous IV infusion of 50 U/kg/h
to maintain an activated clotting time of 180 to 250 s.
Values were monitored every hour with the Hemochron
Junior+ Microcoagulation System (ITC, USA).
Ventilation was provided by a Hamilton G5 ventilator
(Hamilton Medical AG, Switzerland) set to INTELLiVENT -
Adaptive Support Ventilation (ASV) mode. The ventilator
was set to maintain an SpO2 of 95% to 99%, and an EtCO2
of 4.5 to 5.6 kPa. During the non-treated phase of car-
diac arrest, the animals were not ventilated. During the
ECMO-treated phase of cardiac arrest, minute ventilation
was set and maintained at 100% of the predicted minute
volume based on ideal body weight. The fraction of in-
spired oxygen was set to 21%.
Ventricular fibrillation was induced by a high-frequency
burst from a diagnostic decapolar catheter (Response
CSL, St. Jude Medical, USA) advanced to the right
ventricular apex through a jugular venous approach. The
stimulation current amplitude was amplified to two times
the pacing threshold.
Vital functions monitoring
Arterial pressure was measured using routine invasive
pressure transducers (Truwave, Edwards Lifesciences,
LLC, USA) through a pigtail catheter inserted into the
aortic arch. A Swan-Ganz catheter was introduced via a
femoral vein to the pulmonary artery. Electrocardiogram,
invasive blood pressures (aortic arch and jugular vein),
pulse oximetry, capnometry, core temperature (pulmon-
ary artery) and invasive central venous oxygen saturation
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Life Scope TR, Nihon Kohden, Japan and Vigilance II,
Edwards Lifesciences, USA). Brain oxygenation levels
were measured using near-infrared spectroscopy (INVOS
Cerebral/Somatic Oximeter, Somanetics, USA).ECMO
The ECMO circuit consisted of a Levitronix Centrimag
console (Thoratec, USA), centrifugal pump, and tubing
set with HMO 70000 Adult Microporous Membrane
Oxygenator with Softline Coating (MAQUET Cardiopul-
monary AG, Germany) and a mechanical gas blender
(Sechrist, USA). Biomedicus cannulae (Medtronic, USA)
were introduced percutaneously using the standard
Seldinger technique after repeated dilations of the fem-
oral artery and vein. The venous inflow cannula (21F)
was inserted into the inferior vena cava slightly below
the right atrium (the tip position was checked by fluor-
oscopy) and the femoral arterial outflow cannula (15F)
was inserted into the femoral artery. Body temperature
was regulated and kept constant by the oxygenator
heater unit. Blood gases were monitored continuously in
the blood leaving the oxygenator (CDI™ Blood Parameter
Monitoring System 500, Terumo Cardiovascular Systems
Corporation, USA). During the non-treated phase of car-
diac arrest, the pump flow rate was set to 0.5 L/min and
oxygen/air flow was stopped. During the ECMO-treated
phase following cardiac arrest, the pump flow rate was
set to 4.5 L/min and oxygen/air flow was repeatedly ad-
justed to maintain pO2 and pCO2 in the ranges of 10 to
15 kPa and 4.0 to 6.5 kPa, respectively, in blood leaving
the oxygenator. The circuit, console function, and initial
settings were controlled and directed by a perfusionist.Figure 1 Study protocol. Veno-arterial extracorporeal membrane oxygena
ventricular fibrillation (V Fib) was induced by rapid ventricular pacing. After
ECMO flow to 4.5 L/min (100 mL/kg/min); 90 min of reperfusion followed.
performed. Blood samples for the measurement of laboratory parameters (
and 90 min of reperfusion. Stab, stabilization.Experimental protocol
After insertion of all catheters and establishment of
ECMO the animals were stabilized for 10 min. Cardiac
arrest was induced and maintained for 20 min before
circulation was restored by increasing the ECMO flow
rate to 4.5 L/min (100 mL/kg/min). After 60 min of re-
perfusion, defibrillation was attempted up to three times
(300 – 360 – 360 J) to restore sinus rhythm, and the ani-
mals were followed for an additional 30 min. The ECMO
support continued the whole 90 min of reperfusion irre-
spective of defibrillation results (Figure 1).
Animals were randomly assigned to one of the two
groups: NT or HT, with four animals per group. The
core temperature of the animals in the NT group was
maintained at 36.8°C throughout the experiment. The
animals in the HT group were cooled to 33.0°C at the
beginning of reperfusion; the target temperature was
attained in 5 min in all HT animals and was maintained
until the end of experiment.
To simulate clinical conditions, norepinephrine was
administered when the mean arterial blood pressure
remained below 60 mmHg at 10 min after the restor-
ation of circulation. The norepinephrine IV infusion was
started at 0.2 μg/kg/min; this dose could be doubled or
decreased by one-half at 15 min, 20 min, and then every
10 min until the end of the experiment, with a maximal
dose of 1.6 μg/kg/min.Laboratory tests
Blood samples were drawn after 90 min of reperfusion and
were immediately centrifuged. Serum was stored at −70°C
until levels of troponin I (TnI), myoglobin (MGB), creatine
phosphokinase (CPK), alanine aminotransferase (ALT),tion (ECMO) was established and at minimal ECMO flow (0.5 L/min)
20 min of cardiac arrest, circulation was restored by increasing the
After 60 min of reperfusion, up to three defibrillation attempts were
Lab) were taken before and 1 min after arrest and then at 30, 60,
Figure 2 Brain oxygen saturation, mean arterial pressure and
norepinephrine dose progression over the course of the
experiment. Values are expressed as median (min; max). *P<0.05;
NT normothermia; HT hypothermia.
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measured. Blood samples for the measurement of reactive
oxygen metabolites (ROM) and biological antioxidant
potential (BAP) were drawn before CA, 1 min after resto-
ration of blood flow, and after 30, 60 and 90 min of reper-
fusion. ROM and BAP tests were performed immediately
after samples were obtained.
TnI and MGB levels were measured using a chemilu-
minescent immunoassay (Access Immunoassay System,
Beckman Coulter Inc, USA). CPK and ALT levels were
measured according to the method outlined by the
International Federation of Clinical Chemistry, using
the Synchron System (Beckman Coulter Inc, USA). NSE
was measured with an immunoradiometric assay kit
(Beckman Coulter, USA). CysC was measured with a
Cystatin C immunoassay kit (Gentian AS, Norway) util-
izing the immunoturbidimetric method. ROM and BAP
were measured with the Fras 4 Evolvo free radical ana-
lytical system (H&D srl, Italy).
Statistical analysis
Results are expressed as median (min; max). Mann
Whitney test was used to assess differences between
treatment groups in mean arterial blood pressure,
norepinephrine dose, brain oxygen saturation, levels of
oxidative stress markers (ROM and BAP) and all other
laboratory parameters. Fisher’s exact test was used to
test for a difference in resuscitability. Differences were
considered to be statistically significant at P<0.05. All
statistical analyses were performed using GraphPad
Prism 5.0 software (GraphPad, USA).
Results
Blood pressure, brain oxygen saturation, resuscitability
The mean arterial blood pressures, brain oxygen satura-
tions and norepinephrine doses were not significantly
different between treatment groups during the first 60
min of reperfusion (Figure 2). At 70, 80, and 90 min, the
mean arterial blood pressures and brain oxygen satura-
tions were significantly higher in the HT group, despite
the fact that the norepinephrine doses administered to
this group were significantly lower compared with the
NT group (P<0.05; Figure 2). Defibrillation at 60 min
was successful in all HT animals and in one of the NT
animals after three attempts.
Organ damage
Laboratory parameters were analyzed in blood samples
obtained at 90 min of reperfusion. Levels of ALT, CPK,
MGB, and TnI were significantly lower in the HT group
compared with NT group (ALT: 0.36 (0.30; 0.55) versus
0.79 (0.65; 1.27) μkat/L, P<0.05; CPK: 34.2 (26.0; 50.29)
versus 86.0 (81.6; 117.8) μkat/L, P<0.05; MGB: 379.8
(225.3; 566.0) versus 2423.0 (1995.0; 3442.0) ng/L,P<0.05; TnI: 4.8 (4.0; 12.2) versus 35.0 (29.8; 42.2) ng/L,
P<0.05) (Figure 3). The levels of both Cys C and NSE
were close to the lower limit of detection, and no signifi-
cant differences between the HT and NT groups were
observed (Cys C: 0.01 (0.01; 0.04) versus 0.02 (0.1; 0.9)
ng/L, P=0.62; NSE: 0.77 (0.03; 1.53) versus 1.52 (1.29;
1.88) ng/L, P=0.31) (Figure 3).
Figure 3 Serum levels of biomarkers of organ injury. Values are expressed as median (min; max). NT, normothermia; HT hypothermia.
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The levels of ROM prior to and immediately after cardiac
arrest were comparable between the HT and NT groups,
but were significantly lower in the HT group in samples
obtained at 30, 60 and 90 min of reperfusion (Figure 4).
The levels of BAP were comparable between the HT and
NT groups in all measurements.
Discussion
The present study found that mild therapeutic HT (33°C)
is superior to controlled NT (36.8°C) for the maintenanceFigure 4 Serum levels of oxidative stress parameters. Values are expreof blood pressure and brain oxygen saturation, protection
from organ damage and suppression of oxidative stress
following cardiac arrest.
The use of mild therapeutic HT in the treatment of
cardiac arrest survivors has recently been questioned
due to a low level of evidence of its benefits [7,8]; in
addition, spontaneous hyperthermia that may have oc-
curred in the control patients in published clinical trials
seems to be a significant risk factor [10,11]. However,
to date, there have been few publications directly
comparing mild therapeutic HT with controlled NT afterssed as median (min; max). NT, normothermia; HT hypothermia.
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arrest, Jia et al. [14] found increased electroencephalog-
raphy (EEG) bursts, followed by earlier restoration of
continuous EEG activity and lower neurological deficit
in rats treated with mild therapeutic HT compared with
NT or hyperthermic animals. In a recent retrospective
chart review, Horburger et al. [13] described that thera-
peutic HT is associated with a significant improvement in
neurological outcome and 180-day survival compared with
spontaneous NT in out-of-hospital cardiac arrest patients.
These studies are consistent with the observations in
the present study. We found that HT-treated animals
had higher blood pressure and brain oxygen saturation
with lower norepinephrine consumption. However, these
differences reached statistical significance only during
the final 30 min of reperfusion, after successful defibrilla-
tion in all hypothermic animals whereas hemodynamically
effective heart rhythm was restored in only one of four
normothermic pigs. Despite that the rates of successful
defibrillation were not significantly different it is likely that
the increased blood pressure and brain oxygenation in
the hypothermic group were influenced by higher rate of
successful resuscitation. Moreover, the blood pressure dif-
ferences between the HT and NT animals could be further
increased by the continuous ECMO support, irrespective
of the defibrillation results. On the other hand, blood
pressure, tissue saturation, vasopressor consumption and
heart rhythm are dependent parameters; therefore, from a
clinical point of view, it is difficult to speculate which of
these factors plays a more important role. Of note, the nu-
merical values of blood pressure in the only NT animal
with the return of effective heart rhythm after defibrilla-
tion were at least 10 mmHg lower than the corresponding
values from all hypothermic pigs despite higher norepin-
ephrine dose.
We also observed lower levels of TnI, CPK, MBG and
ALT in the HT group, indicating a protective effect of
HT against myocardial, skeletal muscle and liver damage.
The levels of CysC and NSE, markers of kidney and
brain injury, were comparable in hypothermic and nor-
mothermic animals; however, these parameters were
close to the lower limit of detection in both groups. It
can, therefore, be assumed that 90 min of reperfusion is
too short period to detect a substantial release of these
markers into the circulation.
The lower levels of ROM during reperfusion in the HT
group, together with comparable levels of BAP between
groups, indicate that reactive oxygen species formation
may be suppressed by HT, and a lower level of oxidative
stress burden may occur in HT compared with NT. These
results are consistent with our previous observations in
the human population, in which induction of mild HT in
cardiac arrest survivors was associated with a decreased
production of nitrotyrosine and nitric oxide [15].Our study has several limitations. First, we used only
four animals per group that were followed for only ninety
min after cardiac arrest; however, the present study was
designed as a pilot experiment comparing the effects of
HT and NT on clinically relevant parameters in a large-
animal model. Second, the restoration of blood flow by
ECMO in most cardiac arrest cases is not typically
performed in clinical settings. However, ECMO was used
to eliminate the individual variability of blood flow after
resuscitation, and ensured ‘successful’ restoration of circu-
lation in all animals. Finally, the measurement of CysC
and NSE levels as markers of kidney and brain injury
failed to be usable for early organ injury detection; other
markers should be used in future studies of similar design.Conclusions
In porcine model of cardiac arrest, mild HT (33°C) was
superior to controlled NT (36.8°C) for the maintenance of
blood pressure and cerebral oxygenation, prevention of
organ damage and oxidative stress suppression after car-
diac arrest. Prospective clinical trials are needed to con-
firm these experimental results, some of which are already
underway.
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